Severe Hypocalcemia Following a Single Injection of Denosumab in a Patient with Renal Impairment

Overview

Journal J Drug Assess

Date 2016 Aug 19

PMID 27536425

Citations 6

Authors

Draupadi B Talreja

Affiliations

Soon will be listed here.

Abstract

Monitoring renal function and adjusting dosing for patients with impaired renal function are not required with denosumab (60 mg every 6 months). However, these patients have an increased risk for developing hypocalcemia. This case report describes a patient with renal impairment who developed severe hypocalcemia after receiving denosumab.

Citing Articles

Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study.

Inose H, Kato T, Tomizawa S, Ariga A, Motoyoshi T, Fukushima K Bone Rep. 2022; 17:101635.

PMID: 36389625 PMC: 9664386. DOI: 10.1016/j.bonr.2022.101635.

Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?.

Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T Osteoporos Int. 2019; 31(4):655-665.

PMID: 31838550 DOI: 10.1007/s00198-019-05261-7.

New and emerging concepts in the use of denosumab for the treatment of osteoporosis.

Lewiecki E Ther Adv Musculoskelet Dis. 2018; 10(11):209-223.

PMID: 30386439 PMC: 6204627. DOI: 10.1177/1759720X18805759.

High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.

Ishikawa K, Nagai T, Tsuchiya K, Oshita Y, Kuroda T, Ito H Clin Interv Aging. 2018; 13:1929-1934.

PMID: 30349211 PMC: 6183698. DOI: 10.2147/CIA.S180614.

Calcium use in the management of osteoporosis: continuing questions and controversies.

Wilczynski C, Camacho P Curr Osteoporos Rep. 2014; 12(4):396-402.

PMID: 25228457 DOI: 10.1007/s11914-014-0234-z.

References

Gulley J, Wu S, Arlen P, Dahut W . Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clin Genitourin Cancer. 2007; 5(6):403-5. DOI: 10.3816/CGC.2007.n.025. View

Body J, Diel I, Lichinitser M, Kreuser E, Dornoff W, Gorbunova V . Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003; 14(9):1399-405. DOI: 10.1093/annonc/mdg367. View

Rosen L, Gordon D, Tchekmedyian N, Yanagihara R, Hirsh V, Krzakowski M . Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100(12):2613-21. DOI: 10.1002/cncr.20308. View

Pavlakis N, Schmidt R, Stockler M . Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005; (3):CD003474. DOI: 10.1002/14651858.CD003474.pub2. View

Rosen L, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M . Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21(16):3150-7. DOI: 10.1200/JCO.2003.04.105. View

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

Navarro M, Lopez R, Alana M, Ocana A, Leno R, Sanchez F . Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration. J Palliat Med. 2007; 10(6):1226-7. DOI: 10.1089/jpm.2007.0113. View

Henry D, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J . Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29(9):1125-32. DOI: 10.1200/JCO.2010.31.3304. View

Kanis J, McCloskey E, Powles T, Paterson A, Ashley S, Spector T . A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999; 79(7-8):1179-81. PMC: 2362233. DOI: 10.1038/sj.bjc.6690188. View

10.

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

11.

Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren U . Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res. 2000; 19(4C):3383-92. View

12.

Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen H . Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999; 246(1):67-74. DOI: 10.1046/j.1365-2796.1999.00507.x. View

13.

Lipton A, Theriault R, Hortobagyi G, Simeone J, Knight R, Mellars K . Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88(5):1082-90. DOI: 10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z. View

14.

Rosen L, Gordon D, Kaminski M, Howell A, Belch A, Mackey J . Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98(8):1735-44. DOI: 10.1002/cncr.11701. View

15.

Tripathy D, Lichinitzer M, Lazarev A, MacLachlan S, Apffelstaedt J, Budde M . Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2004; 15(5):743-50. DOI: 10.1093/annonc/mdh173. View

16.

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96(11):879-82. DOI: 10.1093/jnci/djh141. View

17.

Stopeck A, Lipton A, Body J, Steger G, Tonkin K, De Boer R . Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28(35):5132-9. DOI: 10.1200/JCO.2010.29.7101. View

18.

Body J, Diel I, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R . Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004; 90(6):1133-7. PMC: 2409647. DOI: 10.1038/sj.bjc.6601663. View

19.

Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y . Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005; 23(15):3314-21. DOI: 10.1200/JCO.2005.05.116. View

20.

Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View